Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin

Journal of Pharmaceutical Sciences

Volumn 99, Issue 7, 2010, Pages 2991-2998

  Zhou, Xueqin ^a   Liu, Dongzhi ^a   Liu, Haiyan ^a   Yang, Qiaoli ^a   Yao, Kangde ^a   Wang, Xueyan ^b   Wang, Lei ^b   Yang, Xinjian ^b  

^a TIANJIN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Baicalin; Low molecular weight chitosan; Permeability; Permeation enhancers; Transdermal drug delivery

Indexed keywords

BAICALIN; CHITOSAN; GLUCOSAMINE;

ANIMAL TISSUE; ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEACETYLATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; SKIN PENETRATION; TRANSDERMAL PATCH;

EID: 77953298728     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22063     Document Type: Article

References (40)

1. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nature Rev Drug Discov 3:115-124. (Pubitemid 38239773)
2. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14: 101-114.
3. Potts RO, Guy RH. 1992. Predicting skin permeability. Pharm Res 9:663-669.
4. Reed BL, Morgan TM, Finnin BC. 2004. Dermal Penetration Enhancers and drug delivery systems involving same. USP 6818226.
5. Rinaudo M. 2006. Chitin and chitosan: Properties and applications. Progr Poly Sci 31:603-632.
6. Di Martino A, Sittinger M, Risbud MV. 2005. Chitosan: A versatile biopolymer for orthopaedic tissue-engineering. Biomaterials 26:5983-5990. (Pubitemid 40805604)
7. Fang J, Sung K, Wang J, Chu C, Chen K. 2002. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J Pharm Pharmacol 54:1329-1337. (Pubitemid 35174177)
8. Cerchiara T, Luppi B, Bigucci F, Orienti I, Zecchi V. 2002. Physically crosslinked chitosan hydrogels as topical vehicles for hydrophilic drugs. J Pharm Pharmacol 54:1453-1459.
9. Smith JM, Wood EJ. 2003. Chitosan as a potential aid to trans-dermal drug delivery. Agro Food Ind Hi-Tech 14:46-49. (Pubitemid 38079924)
10. Yang X, Yuan X, Cai D, Wang S, Zong L. 2009. Low molecular weight chitosan in DNA vaccine delivery via mucosa. Int J Pharm 375:123-132.
11. Lin SB, Lin YC, Chen HH. 2009. Low molecular weight chitosan prepared with the aid of cellulose, lysozyme, and chitinase: Characterisation and antibacterial activity. Food Chem 116:47-53.
12. Tomida H, Fujii T, Furutani N, Michihara A, Yasufuku T, Akasaki K, Maruyama T, Otagiri M, Gebichi MJ, Anraku M. 2009. Antioxidant properties of some different molecular weight chitosans. Carbohydr Res 344:1690-1696.
13. Singla AK, Chawla M. 2001. Chitosan: Some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 53:1047-1067. (Pubitemid 32754936)
14. Lin MC, Tsai MJ, Wen KC. 1999. Supercritical fluid extraction of flavonoids from Scutellariae Radix. J Chromatogr A 830:387-395.
15. Wang R, Kong J, Wang D, Lien LL, Lien EJ. 2007. A survey of Chinese herbal ingredients with liver protection activities. Chin Med 2:5.
16. Lin CC, Shieh DE. 1996. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 24:31-36.
17. Shieh DE, Liu LT, Lin CC. 2000. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anti-cancer Res 20:2861-2865.
18. Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F, Darzynkiewicz Z. 2001. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif 34:293-304.
19. Liu LY, Wei EQ, Zhao YM, Chen FX, Wang ML, Zhang WP, Chen Z. 2005. Protective effects of baicalin on oxygen/glucose deprivation- and NMDA-induced injuries in rat hippocampal slices. J Pharm Pharmacol 57:1019-1025.
20. Zhao YL, Li HL, Gao ZH, Xu HB. 2005. Effect of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury. Eur J Pharmacol 509:195-200.
21. Qin SH, Liu HG. 2003. Progress in research on in vivo pharmacokinetics of baicalin(in Chinese). J Guangxi Tradit Chin Med Univ 6:72-74.
22. Qiu F, He Z, Li H. 2003. HPLC analyses and pharmacokinetic studies of baicalin and oxymatrine in rabbits. Pharmazie 58:616-619.
23. Yoshizuka K, Ohta H, Inoue K, Kitazaki H, Ishimaru M. 1996. Selective separation of flavonoids with a polyvinyl alcohol membrane. J Membr Sci 118:41-48. (Pubitemid 27031530)
24. Lai MY, Hsiu SL, Tsai SY, Hou YC, Chao PDL. 2003. Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats. J Pharm Pharmacol 55:205-209.
25. Thomas BJ, Finnin BC. 2004. The transdermal revolution. Drug Discov Today 9:697-703.
26. Purdon CH, Azzi CG, Zhang J, Smith EW, Maibach HI. 2004. Penetration enhancement of transdermal delivery - Current permutations and limitations. Crit Rev Ther Drug Carrier Syst 21:97-132. (Pubitemid 41647584)
27. Gupta KC, Jabrail FH. 2006. Effects of degree of deacetylation and cross-linking on physical characteristics, swelling and release behavior of chitosan microspheres. Carbohydr Polym 66:43-54.
28. Swart H, Breytenbach JC, Hadgraft J, du Plessis J. 2005. Synthesis and transdermal penetration of NSAID glycoside esters. Int J Pharm 301:71-79.
29. Carelli V, Di Colo G, Nannipieri E, Serafini ML. 1992. Enhancement effects in the permeation of Alprazolam through hairless mouse skin. Int J Pharm 88:89-97. (Pubitemid 23000411)
30. Je JY, Cho YS, Kim SK. 2006. Cytotoxic activities of water-soluble chitosan derivatives with different degree of deacetylation. Bioorg Med Chem Lett 16:2122-2126. (Pubitemid 43351063)
31. Yang Y, Liu WS, Han BQ, Liu B, Fu CW. 2006. Protective effects of chitosan oligosaccharide and its derivatives against carbon tetrachloride- induced liver damage in mice. Hepatol Res 35:178-184.
32. Sonvico F, Cagnani A, Rossi A, Motta S, Bari MTD, Cavatorta F, Alonso MJ, Deriu A, Colombo P. 2006. Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. Int J Pharm 324:67-73. (Pubitemid 44548291)
33. Yalpani M, Hall LD. 1984. Some chemical and analytical aspects of polysaccharide modifications. III. Formation of branched-chain, soluble chitosan derivatives. Macromolecules 17:272-281.
34. Kotze AF, LueBen HL, de Boer AG, Verhoef JC, Junginger HE. 1998. Chitosan for enhanced intestinal permeability: Prospects for derivatives soluble in neutral and basic environments. Eur J Pharm Sci 7:145-151.
35. Park JW, Choi KH. 1983. Acid-base equilibria and related properties of chitosan. Bull Kor Chem Soc 4:68-72.
36. Wang QZ, Chen XG, Liu N, Wang SX, Liu CS, Meng XH, Liu CG. 2006. Protonation constants of chitosan with different molecular weight and degree of deacetylation. Carbohydr Polym 65:194-201. (Pubitemid 44107503)
37. Anthonsen MW, SmidsrΦd O. 1995. Hydrogen ion titration of chitosans with varying degrees of N-acetylation by monitoring induced 1H-NMR chemical shifts. Carbohydr Polym 26:303-305.
38. Dodane V, Vilivalam VD. 1998. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1:246-253.
39. Prabaharan M, Mano JF. 2005. Chitosan-based particles as controlled drug delivery systems. Drug Deliv 12:41-57. (Pubitemid 40066260)
40. Williams AC, Barry BW. 2004. Penetration enhancers. Adv Drug Deliv Rev 56:603-618.